{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:06:39Z","timestamp":1747188399470,"version":"3.40.5"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In March 2020, there were no treatment options for COVID\u201019. Passive immune therapy including anti\u2010SARS\u2010CoV\u20102 hyperimmune globulin (hIVIG) was a logical candidate for COVID\u201019 therapeutic trials, given past success treating emerging pathogens with endogenous neutralizing antibodies. We established a plasma collection protocol for persons recovered from COVID\u201019. To speed recruitment in the first U.S. hotspot, Seattle, Washington, federal and state public health agencies collaborated with Bloodworks Northwest to collect convalescent plasma (CP) for manufacturing hIVIG. During March\u2013December 2020, we identified and recruited prospective CP donors via letters to persons recovered from COVID\u201019 with laboratory\u2010confirmed SARS\u2010CoV\u20102 infection. Prospective donors were pre\u2010screened and administered a medical history survey. Anti\u2010SARS\u2010CoV\u20102 neutralizing antibody (NAb) titers were classified as qualifying (\u22651:80) or non\u2010qualifying (&lt;1:80) for enrollment based on a live virus neutralization assay. Generalized estimating equations were used to identify characteristics of donors associated with qualifying versus nonqualifying NAb titers. Overall, 21,359 letters resulted in 3207 inquiries, 2159 prescreenings with laboratory\u2010confirmed SARS\u2010CoV\u20102 infection, and 573 donors (27% of all pre\u2010screenings with confirmed infection) who provided a screening plasma donation. Of 573 donors screened, 254 (44%) provided plasma with qualifying NAb titers, resulting in 1284\u2009units for hIVIG manufacture. In a multivariable model, after adjusting for other factors, time (60\u2009days) from COVID\u201019 symptom onset to screening was associated with lower odds of qualifying NAb (adjusted odds ratio\u00a0=\u00a00.67, 95% CI: 0.48\u20130.94). The collaboration facilitated a rapid response to develop and provide hIVIG for clinical trials and CP for transfusion. Only 1 in 12 donor inquiries resulted in a qualifying plasma donation. Challenges included recruitment and the relatively low percentage of persons with high NAb titers and limited screening capacity. This resource\u2010intensive collaboration may not be scalable but informs preparedness and response strategies for plasma collection in future epidemics. Operational readiness plans with templates for screening, consent, and data collection forms are recommended.<\/jats:p>","DOI":"10.1111\/trf.16630","type":"journal-article","created":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T17:45:53Z","timestamp":1631468753000},"page":"2814-2824","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["<i>How do I<\/i>\u2026 facilitate a rapid response to a public health emergency requiring plasma collection with a public\u2013private partnership?"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-9052","authenticated-orcid":false,"given":"Maureen J.","family":"Miller","sequence":"first","affiliation":[{"name":"Epidemic Intelligence Service U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"COVID\u201019 Response Team U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Skrzekut","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-9466","authenticated-orcid":false,"given":"Ian","family":"Kracalik","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-9058","authenticated-orcid":false,"given":"Jefferson M.","family":"Jones","sequence":"additional","affiliation":[{"name":"COVID\u201019 Response Team U.S. Centers for Disease Control and Prevention  Atlanta Georgia USA"},{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn H.","family":"Lofy","sequence":"additional","affiliation":[{"name":"Washington State Department of Health  Tumwater Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Rebecca","family":"Haley","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Duvenhage","sequence":"additional","affiliation":[{"name":"Division of Clinical Research National Institute of Allergy and Infectious Diseases  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Bonnett","sequence":"additional","affiliation":[{"name":"Clinical Monitoring Research Program Directorate Frederick National Laboratory for Cancer Research  Frederick Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Holbrook","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Integrated Research Facility NIAID  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Higgs","sequence":"additional","affiliation":[{"name":"NIAID  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0499","authenticated-orcid":false,"given":"Sridhar V.","family":"Basavaraju","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Paranjape","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"CDC COVID Data Tracker.https:\/\/covid.cdc.gov\/covid-data-tracker\/#datatracker-home."},{"key":"e_1_2_8_3_1","unstructured":"Determination that a Public Health Emergency Exists.U.S. Department of Health and Human Services;2020."},{"key":"e_1_2_8_4_1","unstructured":"Emergency Use Authorization Declaration.U.S. Department of Health and Human Services;2020."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2209.151164"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02651.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4940"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu396"},{"key":"e_1_2_8_13_1","unstructured":"INSIGHT\u2010013Inpatient Treatment with Anti\u2010Coronavirus Immunoglobulin (ITAC).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04546581."},{"key":"e_1_2_8_14_1","unstructured":"FDA.Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID\u201319 Treatment Another Achievement in Administration's Fight Against Pandemic [press release];2020."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16378"},{"key":"e_1_2_8_16_1","unstructured":"Washington State Department of HealthCOVID\u201019 Data Dashboard.https:\/\/www.doh.wa.gov\/Emergencies\/COVID19\/DataDashboard."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu396"},{"key":"e_1_2_8_18_1","unstructured":"COVID\u201019 survivors may help save lives by donating blood [press release]; 2020."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13050893"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15789"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2035678"},{"key":"e_1_2_8_24_1","unstructured":"U.S. Food and Drug Administration.Investigational COVID\u201019 Convalescent Plasma Guidance for Industry;2021."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16328"},{"key":"e_1_2_8_26_1","unstructured":"FDA.Updates Emergency Use Authorization for COVID\u201019 Convalescent Plasma to Reflect New Data [press release]; 2021."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16630","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T20:47:28Z","timestamp":1693342048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/trf.16630"],"URL":"https:\/\/doi.org\/10.1111\/trf.16630","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2021,9,12]]},"assertion":[{"value":"2021-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}